Tuesday, July 4, 2023

This drug developed by AI for lungs disease enters human clinical trials

Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring in the lungs, has a new AI-designed drug named INS018-055 that has entered human clinical trials. Insilico Medicine has developed this drug named using its generative AI platform. INS018-055 clinical trials taking place in China could offer an alternative treatment with fewer side effects. Insilico Medicine is also developing two more drugs using AI, a Covid-19 drug in Phase one trial, and a USP1 inhibitor for the treatment of solid tumours that has already received FDA approval. https://ift.tt/wUZB8DE
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Russia's finance minister says Russian companies have begun using bitcoin and other digital currencies in international payments to counter Western sanctions (Gleb Bryanski/Reuters)

Gleb Bryanski / Reuters : Russia's finance minister says Russian companies have begun using bitcoin and other digital currencies in i...